BMS to Spotlight Pipeline at TD Cowen Health Meet
NEW YORK, Feb. 24, 2026 — Bristol Myers Squibb announced its participation in the upcoming TD Cowen 46th Annual...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
NEW YORK, Feb. 24, 2026 — Bristol Myers Squibb announced its participation in the upcoming TD Cowen 46th Annual...
Dateline – November 17 2025 | Tokyo, Japan & Cambridge/London, UK Nxera Pharma announced a major restructuring initiative aimed...
